Phoebe Gruccio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Phoebe Gruccio has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Amelia D. Badipour
Affiliation Division of Infectious Diseases, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States of America
1 shared publication- Christopher C. Moore
Division of Infectious Diseases and International Health, Department of Medicine, University of Virginia, Charlottesville, Virginia, USA
1 shared publication Conrad Muzoora
Affiliation Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda
1 shared publicationEdwin Nuwagira
Affiliations Division of Infectious Diseases, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States of America, Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda, Tuberculosis Treatment Unit, Mbarara Regional Referral Hospital, Mbarara, Uganda
1 shared publication- Eva Otoupalova
Pulmonary and Critical Care, University of Virginia, Charlottesville, VA, United States
1 shared publication Jeffrey Sturek
Affiliation Division of Pulmonology and Critical Care Medicine, Department of Medicine, University of Virginia, Charlottesville, Virginia, United States of America
1 shared publication
Latest Publications
- Open Access
- 9 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004429
A narrative review of the pathophysiology of sepsis in sub-Saharan Africa: Exploring the potential for corticosteroid therapy
Sepsis remains a significant global health threat with a disproportionate burden in low-income countries including those in sub-Saharan Africa where case fatality rates are as high as 30% to 50%. Defined as a severe systemic response to infection, sepsis leads to widespread immune dysregulation and organ dysfunction, including adrenal insufficiency. Critical illness-related corticosteroid insufficiency (CIRCI) arises from dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, altered cortisol metabolism, and tissue resistance to glucocorticoids, all of which can occur during sepsis. Clinical trials of corticosteroids for the treatment of patients with sepsis and septic shock have shown improvements in shock reversal, and in some studies, patient survival; however, their role in the treatment of sepsis in sub-Saharan Africa is unknown. The incidence of sepsis in sub-Saharan Africa is compounded by high rates of human immunodeficiency virus (HIV) and co-infections, including tuberculosis (TB), which is the leading cause of sepsis. Both HIV and TB can cause immune dysregulation and adrenal insufficiency, which may exacerbate CIRCI and prolong shock. Existing sepsis research has been predominantly conducted in high-income countries and has largely excluded people living with HIV or TB. Therefore, there is a need to better understand sepsis and CIRCI pathophysiology in the context of specific regional host and pathogen characteristics. In this narrative review, we explored the pathophysiology of sepsis in sub-Saharan Africa including the existing literature on the immune response to sepsis and the prevalence of adrenal insufficiency in patients with HIV and TB, with a focus on the implications for corticosteroid management. We found a compelling need to further evaluate corticosteroids for the treatment of sepsis in Africa.
- 9 April 2025
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 5 (4) , e0004429
Open AccessA narrative review of the pathophysiology of sepsis in sub-Saharan Africa: Exploring the potential for corticosteroid therapy
Sepsis remains a significant global health threat with a disproportionate burden in low-income countries including those in sub-Saharan Africa where case fatality rates are as high as 30% to 50%. Defined as a severe systemic response to infection, sepsis leads to widespread immune dysregulation and organ dysfunction, including adrenal insufficiency. Critical illness-related corticosteroid insufficiency (CIRCI) arises from dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, altered cortisol metabolism, and tissue resistance to glucocorticoids, all of which can occur during sepsis. Clinical trials of corticosteroids for the treatment of patients with sepsis and septic shock have shown improvements in shock reversal, and in some studies, patient survival; however, their role in the treatment of sepsis in sub-Saharan Africa is unknown. The incidence of sepsis in sub-Saharan Africa is compounded by high rates of human immunodeficiency virus (HIV) and co-infections, including tuberculosis (TB), which is the leading cause of sepsis. Both HIV and TB can cause immune dysregulation and adrenal insufficiency, which may exacerbate CIRCI and prolong shock. Existing sepsis research has been predominantly conducted in high-income countries and has largely excluded people living with HIV or TB. Therefore, there is a need to better understand sepsis and CIRCI pathophysiology in the context of specific regional host and pathogen characteristics. In this narrative review, we explored the pathophysiology of sepsis in sub-Saharan Africa including the existing literature on the immune response to sepsis and the prevalence of adrenal insufficiency in patients with HIV and TB, with a focus on the implications for corticosteroid management. We found a compelling need to further evaluate corticosteroids for the treatment of sepsis in Africa.